异黏蛋白与叉头框蛋白M1在肝细胞癌中的表达及其临床意义

doi:10.3969/j.issn.1004-616x.2021.05.006

Abstract

Abstract: OBJECTIVE: To explore relationships between expression of metadherin (MTDH) and forkhead box M1 (FoxM1) in hepatocellular carcinomas (HCC) and the clinicopathological features and prognosis of patients. METHODS: Surgical specimens from 156 HCC patients were usedof. Expressions of MTDH and FoxM1 were detected by immunohistochemistry and to analyze the relationship between the expression of MTDH and FoxM1 and the clinical pathological characteristics and prognosis. RESULTS: Immunohistochemical results showed that positive rates of MTDH was 71.2% (111/156). Expressions of MTDH were significantly related to tumor numbers,TNM stages,microvascular invasions,satellite nodules (P < 0.05). Positive rates of FoxM1 was 64.7% (101/156). Expressions of FoxM1 were significantly related to cirrhosis, tumor numbers, TNM stages, microvascular invasions, satellite nodules (P < 0.05). RT-PCR showed that expression of MTDH and FoxM1 was significantly increased. Spearman correlation analyses showed that there was a significant correlation between MTDH and FoxM1. Results from the Kaplan-Meier survival analyses showed that survival times were significantly related to TNM stages, microvascular invasions, satellite nodules, expressions of MTDH and FoxM1 (P < 0.05). Results from the multivariate Cox regression analyses showed that TNM stages and MTDH expressions were the main factors which influenced survival times of the patients. CONCLUSION: For HCC patients,MTDH and FoxM1 expressions were related to many clinical factors. Particularly,MTDH expression was a prognostic factor and there was a significant correlation between MTDH and FoxM1 expressions.

Key words: hepatocellular carcinoma, metadherin, forkhead box M1, immunohistochemistry, prognosis

CLC Number:

R735.7

JIAO Wenjing, ZHANG Jinyan, MA Ming, GUO Xiujuan, FENG Junhua, SHAO Junguo, JIAO Wenpeng. Expression and clinical significance of MTDH and FoxM1 in hepatocellular carcinomas[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(5): 349-353,359.

References

[1] BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA:Cancer J Clin, 2018, 68(6):394-424.
[2] HUANG Y, LI L P. Progress of cancer research on astrocyte elevated gene-1/Metadherin (Review)[J]. Oncol Lett, 2014, 8(2):493-501.
[3] KHAN M, SARKAR D. The scope of astrocyte elevated gene-1/metadherin (AEG-1/MTDH) in cancer clinicopathology:a review[J]. Genes (Basel), 2021, 12(2):308.
[4] LIANG C, SHANGGUAN J, YANG L, et al. Downregulation of astrocyte elevated gene-1 expression inhibits the development of vasculogenic mimicry in gliomas[J]. Exp Ther Med, 2021, 21(1):22.
[5] 李宝华, 刘平, 王新. MTDH、Tmem16a在脉络膜黑色素瘤中的表达及意义[J]. 临床眼科杂志, 2017, 25(6):481-483.
[6] WANG X L, CAI L J, YE F, et al. Elevated expression of MTDH predicts better prognosis of locally advanced HER-2 positive breast cancer patients receiving neoadjuvant chemotherapy plus trastuzumab[J]. Medicine (Baltimore), 2019, 98(36):e16937.
[7] EMDAD L, LEE S G, SU Z Z, et al. Astrocyte elevated gene-1(AEG-1) functions as an oncogene and regulates angiogenesis[J]. Proc Natl Acad Sci USA, 2009, 106(50):21300-21305.
[8] EMDAD L, DAS S K, DASGUPTA S, et al. AEG-1/MTDH/LYRIC:signaling pathways, downstream genes, interacting proteins, and regulation of tumor angiogenesis[J]. Adv Cancer Res, 2013, 120:75-111.
[9] RAYCHAUDHURI P, PARK H J. FoxM1:a master regulator of tumor metastasis[J]. Cancer Res, 2011, 71(13):4329-4333.
[10] KATOH M, KATOH M. Human FOX gene family (Review)[J]. Int J Oncol, 2004, 25(5):1495-1500.
[11] 孔飞飞, 姜斌. FoxM1在肿瘤转移过程中作用的研究进展[J]. 医学综述, 2014, 20(2):251-253.
[12] 许良中, 杨文涛. 免疫组织化学反应结果的判断标准[J]. 中国癌症杂志, 1996, 6(4):229-231.
[13] YANG J D, HAINAUT P, GORES G J, et al. A global view of hepatocellular carcinoma:trends, risk, prevention and management[J]. Nat Rev Gastroenterol Hepatol, 2019, 16(10):589-604.
[14] CHEN Z Q, XIE H, HU M M, et al. Recent progress in treatment of hepatocellular carcinoma[J]. Am J Cancer Res, 2020, 10(9):2993-3036.
[15] LI S, SAVIANO A, ERSTAD D J, et al. Risk factors, pathogenesis, and strategies for hepatocellular carcinoma prevention:emphasis on secondary prevention and its translational challenges[J]. J Clin Med, 2020, 9(12):3817.
[16] MALIK A, THANEKAR U, AMARACHINTHA S, et al. "complimenting the complement":mechanistic insights and opportunities for therapeutics in hepatocellular carcinoma[J]. Front Oncol, 2020, 10:627701.
[17] ASH S C, YANG D Q, BRITT D E. LYRIC/AEG-1 overexpression modulates BCCIPalpha protein levels in prostate tumor cells[J]. Biochem Biophys Res Commun, 2008, 371(2):333-338.
[18] CHU P Y, WANG S M, CHEN P M, et al. Expression of MTDH and IL-10 is an independent predictor of worse prognosis in ER-negative or PR-negative breast cancer patients[J]. J Clin Med, 2020, 9(10):3153.
[19] ZHANG H, ZOU C, QIU Z, et al. CPEB3-mediated MTDH mRNA translational suppression restrains hepatocellular carcinoma progression[J]. Cell Death Dis, 2020, 11(9):792.
[20] YAO Y, LI H Z, QIAN B J, et al. Crypotanshione reduces the expression of metadherin in DU145 prostate cancer cells[J]. Natl J Androl, 2015, 21(9):782-787.
[21] LI W, LIN S, LI W, et al. IL-8 interacts with metadherin promoting proliferation and migration in gastric cancer[J]. Biochem Biophys Res Commun, 2016, 478(3):1330-1337.
[22] WANG Z, WANG L, HU J, et al. RARRES3 suppressed metastasis through suppression of MTDH to regulate epithelialmesenchymal transition in colorectal cancer[J]. Am J Cancer Res, 2015, 5(6):1988-1999.
[23] LIAO G B, LI X Z, ZENG S, et al. Regulation of the master regulator FOXM1 in cancer[J]. Cell Commun Signal, 2018, 16(1):57.
[24] YANG X, YANG S, SONG J, et al. Dysregulation of miR-23b-5p promotes cell proliferation via targeting FOXM1 in hepatocellular carcinoma[J]. Cell Death Discov, 2021, 7(1):47.
[25] SONG B N, CHU I S. A gene expression signature of FOXM1 predicts the prognosis of hepatocellular carcinoma[J]. Exp Mol Med, 2018, 50(1):e418.
[26] LIU J, LI J P, WANG K, et al. Aberrantly high activation of a FoxM1-STMN1 axis contributes to progression and tumorigenesis in FoxM1-driven cancers[J]. Signal Transduct Target Ther, 2021, 6(1):42.
[27] LAISSUE P. The forkhead-box family of transcription factors:key molecular players in colorectal cancer pathogenesis[J]. Mol Cancer, 2019, 18(1):5.
[28] LI M, YANG J, ZHOU W, et al. Activation of an AKT/FOXM1/STMN1 pathway drives resistance to tyrosine kinase inhibitors in lung cancer[J]. Br J Cancer, 2017, 117(7):974-983.
[29] ABDELJAOUED S, BETTAIEB L, NASRI M, et al. Forkhead box M1(FOXM1) expression predicts disease free survival and may mediate resistance to chemotherapy and hormonotherapy in male breast cancer[J]. Breast Dis, 2018, 37(3):109-114.
[30] 宋莉平, 王宇. 转录因子FoxM1在肿瘤耐药中的研究进展[J]. 现代肿瘤医学, 2019, 27(22):4107-4111.
[31] KALATHIL D, JOHN S, NAIR A S. FOXM1 and cancer:faulty cellular signaling derails homeostasis[J]. Front Oncol, 2020, 10:626836.

Expression and clinical significance of MTDH and FoxM1 in hepatocellular carcinomas

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	PENG Youbin, LIN Hao, LI Ming, HUANG Haihua. Expression of TPX2 and its clinicalsignificance in non-muscle-invasive bladder cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(1): 30-34.
[2]	ZHU Xinping, JIA Di, LIN Shaohui, LIU Chen, LI Jingyi, ZHAO Weiming. Inhibitory effects of a novel polyoxometalate drug {BiW₈O₃₀}on liver cancer SK-HEP-1 cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(1): 47-52,66.
[3]	JIAO Wenpeng, HOU Lin, CUI Meijuan, JIAO Wenjing, MA Ming, ZHANG Jinyan. Expression of miR-93-5p and miR-106b-5p in alcohol-related liver cancer and its clinical significance [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(6): 430-434.
[4]	GAO Xiaobin, WU Xueliang, WANG Shengjie, SUN Guangyuan, WANG Wenjing, LIANG Feng, ZHAO Yifeng, LIU Zhenxian, ZHANG Yingchun. Expression of TRIM59 and its correlations with clinicopathological features in colorectal cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(6): 446-450.
[5]	ZHANG Shimin, ZHAO Ruijun. Expression of protein tyrosine phosphatase receptor J in breast cancer tissues and its relationship with clinical prognosis [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(4): 276-279,285.
[6]	LIU Xiaoxia, LI Weixia, LI Zhijia, SU Zhenjun, DUAN Xiaohui, HAN Weiwen, WANG Yunxiao, HE Xiaolei, Lu Linlin, JIA Jinhai. Correlations between glutathione peroxidase in serum and clinicopathological outcomes of advanced non-small cell lung cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(4): 286-290,295.
[7]	ZHANG Yuling, WU Jundong, PANG Dongyue, CHEN Chunfa. Changes of Ki67 expression before and after neoadjuvant chemotherapy as a predictor for therapeutic response and rognosis in breast cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(3): 230-235,245.
[8]	SHI Hailin, HE Tianji, LIU Feng, CAI Menghui, GE Bo. Prognostic value of TCGA-database mutation burden in muscle-invasive bladder cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(6): 430-437,443.
[9]	LIN Kaihuang, CAI Gaoyang, LIU Xincheng. Effect of mTOR inhibitor AZD2014 on proliferation of hepatoma HCC cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(6): 448-451.
[10]	DING Yawen, JIAO Wenjing, WANG Pengyu, LU Gang, MA Ming. Immunophenotype characteristics of plasma cells and clinical significance in multiple myeloma patients [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(6): 464-468,489.
[11]	YANG Xiuyuan, PAN Yuelong. Expression of CD10 protein in colorectal carcinomas and its clinical significance [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(5): 344-349.
[12]	SHAO Junguo, JIAO Wenjing, WANG Xuexiao, ZHANG Jinyan, MA Ming. Clinical significance of mi-429 and Bmi-1 mRNA expressions in lung carcinoma tissues [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(5): 369-373.
[13]	Lü Yanping, WU Chuancheng, YANG Shuangfeng, HE Chenzhou, HAN Renjie, YAN Wei, LIU Baoying. Relationship between differentially expressed miRNA-SNPs and prognosis of gastric cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(5): 380-386.
[14]	GUO Xiujuan, DU Yanyan, YAN Xi, ZHAO Xuetao, HAN Lina, WU Yipeng, WANG Xuexiao, MA Ming. Expression and clinical significance of CREB in esophageal squamous cell carcinoma tissues [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(5): 387-390,394.
[15]	YANG Li, ZHANG Mengxian, ZHANG Wei, XIONG Yingyou, CHEN Shiyong, FANG Chengxiang. Data mining to investigate expression and significance of aurora kinase A in esophageal carcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(3): 221-228.